Across TCGA pan-cancer cohorts, C2CD4A Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated C2CD4A data layer compared with 24 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher C2CD4A Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated C2CD4A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC are the cancer types where C2CD4A Mutation most reproducibly stratifies survival.